Lexicon Pharmaceuticals CEO Lonnel Coats' 2020 pay stays at $3.9M
Lexicon Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: March 19, 2021
Lexicon Pharmaceuticals reported fiscal year 2020 executive compensation information on March 19, 2021.
In 2020, seven executives at Lexicon Pharmaceuticals received on average a compensation package of $1.8M, a 3% increase compared to previous year.
Average pay of disclosed executives at Lexicon Pharmaceuticals
Lonnel Coats, Chief Executive Officer, received $3.9M in total, which is about the same as previous year. 48% of Coats' compensation, or $1.9M, was in option awards. Coats also received $473K in bonus, $669K in salary, $840K in stock awards, as well as $12K in other compensation.
For fiscal year 2020, the median employee pay was $185,844 at Lexicon Pharmaceuticals. Therefore, the ratio of Lonnel Coats' pay to the median employee pay was 21 to one.
Pablo Lapuerta, Chief Medical Officer, received a compensation package of $1.9M, which increased by 28% compared to previous year. 36% of the compensation package, or $667K, was in other compensation.
Jeffrey L. Wade, Chief Financial Officer, earned $1.6M in 2020, a 1% increase compared to previous year.
Praveen Tyle, Executive Vice President, Research and Development, received $1.6M in 2020, which decreases by 4% compared to 2019.
Alexander A. Santini, Former Executive Vice President and Chief Commercial Officer, earned $1.4M in 2020, a 7% decrease compared to previous year.
Alan J. Main, Executive Vice President, Innovation and Chemical Sciences, received $1.3M in 2020, which decreases by 6% compared to 2019.
Brian T. Crum, General Counsel, earned $1.2M in 2020, a 30% increase compared to previous year.
Related executives
Lonnel Coats
Lexicon Pharmaceuticals
Chief Executive Officer
Jeffrey Wade
Lexicon Pharmaceuticals
Chief Financial Officer
Brian Crum
Lexicon Pharmaceuticals
General Counsel
Alan Main
Lexicon Pharmaceuticals
Executive Vice President, Innovation and Chemical Sciences
Praveen Tyle
Lexicon Pharmaceuticals
Executive Vice President, Research and Development
Pablo Lapuerta
Lexicon Pharmaceuticals
Chief Medical Officer
Alexander Santini
Lexicon Pharmaceuticals
Former Executive Vice President and Chief Commercial Officer
You may also like
Source: SEC filing on March 19, 2021.